Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?Zacks Investment Research • Wednesday
FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast CancerBusiness Wire • Monday
FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancerGlobeNewsWire • Monday
Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratoriesPRNewsWire • Monday
Roche's Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathyGlobeNewsWire • Monday
Genentech's Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous NephropathyBusiness Wire • Monday
CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for systemic lupus erythematosus (SLE)GlobeNewsWire • 11/13/26
Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory SystemsBusiness Wire • 11/10/26
Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer's Disease Portfolio at CTAD 2026Business Wire • 11/10/26
Roche presents new data across pharmaceuticals and diagnostics from its growing Alzheimer's disease portfolio at CTAD 2026GlobeNewsWire • 11/10/26
Chai Discovery Announces Collaboration with Roche in AI-Driven Drug DiscoveryBusiness Wire • 11/05/26
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needsPRNewsWire • 11/02/26
Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And DetractorsSeeking Alpha • 10/28/26
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesotheliomaGlobeNewsWire • 10/28/26
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratoriesGlobeNewsWire • 10/27/26
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung CancerBusiness Wire • 10/25/26
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancerGlobeNewsWire • 10/25/26
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)Business Wire • 10/23/26
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)GlobeNewsWire • 10/23/26